The urgent correction notice is the latest in a series of actions related to the safety of Impella devices.
J&J corrects Impella heart pumps over issue linked to 22 serious injuries Read More »
Pulsed field ablation has fueled strong sales growth for the firm’s electrophysiology business over the past two years. However, the pace has slowed in recent quarters.
Boston Scientific continues to see electrophysiology success despite slowdown in growth Read More »
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas Read More »
The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.
Express Scripts reaches ‘landmark’ settlement with FTC in insulin suit Read More »
The agency quietly released a memo updating MA plans on how it’s approaching risk adjustment data validation audits after a Texas judge’s ruling last year threw the expanded reviews into doubt.
CMS presses ahead on accelerated Medicare Advantage audits Read More »
The new research published in Health Affairs adds to concerns about low physician participation in the safety-net insurance program, especially among mental health practitioners.
One-quarter of Medicaid doctors don’t actually treat Medicaid patients: study Read More »
Pulsed field ablation has fueled strong sales growth for the firm’s electrophysiology business over the past two years. However, the pace has slowed in recent quarters.
Spending on the tests, which analyze genetic material from both people and pathogens, rose 20% year over year in 2024, the analysis found.
Genetic testing takes greater share of Medicare Part B test spending: OIG Read More »
The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions Read More »
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough Read More »
